Eli Lilly ousts CFO Josh Smiley after ‘inappropriate relationship’ with employee, appoints successor in Anat Ashkenazi

February 9, 2021 07:50 AM EST

Eli Lilly ousts CFO Josh Smiley after 'inappropriate relationship' with employee, appoints successor in Anat Ashkenazi

Kyle Blankenship

Managing Editor

Eli Lilly CFO Josh Smiley was touted as one of David Rick’s new blood hires back in 2017, when the helmsman looked to overhaul the listless drugmaker’s top leadership. But now, just over three years into the job, Smiley is out after allegations of inappropriate behavior with other team members.

Lilly will promote Anat Ashkenazi, previously the CFO of Lilly Research Labs, to the larger company’s lead finance role after Smiley was dismissed following an “inappropriate personal relationship” with an employee, the drugmaker said Tuesday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

July 24, 2021 06:00 AM EDT

Weekly

Novartis reshuffles its wild cards; Tough sell for Biogen? Googling proteins; Ken Frazier's new gig; and more

Amber Tong

Senior Editor

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

If you enjoy the People section in this report, you may also want to check out Peer Review, my colleagues Alex Hoffman and Kathy Wong’s comprehensive compilation of comings and goings in biopharma.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Demis Hassabis, DeepMind CEO (Qianlong/Imaginechina via AP Images)

July 23, 2021 11:15 AM EDT

Discovery

Google's DeepMind opens its protein database to science — potentially cracking drug R&D wide open

Jason Mast

Editor

Nearly a year ago, Google’s AI outfit DeepMind announced they had cracked one of the oldest problems in biology: predicting a protein’s structure from its sequence alone. Now they’ve turned that software on nearly every human protein and hundreds of thousands of additional proteins from organisms important to medical research, such as fruit flies, mice and malaria parasite.

The new database of roughly 350,000 protein sequences and structures represents a potentially monumental achievement for the life sciences, one that could hasten new biological insights and the development of new drugs. DeepMind said it will be free and accessible to all researchers and companies.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

July 21, 2021 07:17 PM EDTUpdated July 23, 03:30 PM

Pharma

Inside Biogen's scramble to sell Aduhelm: Project 'Javelin' and pressure to ID as many patients as possible

Zachary Brennan

Senior Editor

In anticipation of Aduhelm’s approval for Alzheimer’s in June, Biogen employees were directed to identify and guarantee treatment centers would administer the drug through a program called “Javelin,” a senior Biogen employee told Endpoints News.

The program identified about 800 centers for use, he said, and Biogen now pays for the use of bioassays to identify beta amyloid in potential patients having undergone a lumbar puncture procedure, the employee said — and one center preparing to administer the drug confirmed its participation in the bioassay program.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

ENDPOINTS CAREERS

Director-Regulatory

Icosavax, Inc.

Seattle, WA, USA

view job offer post your job now

July 23, 2021 09:49 AM EDT

Pharma

FDA+

EMA rejects FDA-approved Parkinson's drug, signs off on Moderna vaccine use in adolescents ahead of FDA

Zachary Brennan

Senior Editor

The European Medicines Agency on Friday rejected Kyowa Kirin’s Parkinson’s disease drug Nouryant (istradefylline), which the US FDA approved in 2019 under the brand name Nourianz.

EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.”

July 23, 2021 06:58 AM EDT

R&D

Pharma

6 top drugmakers offer perspectives on FDA's new covariates in RCTs guidance

Zachary Brennan

Senior Editor

Back in May, the FDA revised and expanded a 2019 draft guidance that spells out how to adjust for covariates in the statistical analysis of randomized controlled trials.

Building on the ICH’s E9 guideline on the statistical principles for clinical trials, the 3-page draft was transformed into an 8-page draft, with more detailed recommendations on linear and nonlinear models to analyze the efficacy endpoints in RCTs.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Al Sandrock, Biogen R&D chief (Biogen via YouTube)

July 22, 2021 04:37 PM EDTUpdated July 23, 05:35 AM

Pharma

Biogen has a shaky end to H1 with a $542M write-off adding to its woes — but analysts see big revenue ahead for Aduhelm

Jason Mast

Editor

All eyes at Biogen’s Q2 earnings call Thursday were on Aduhelm, but investors also got a glimpse of what Biogen would have faced had the FDA not opted to approve their controversial Alzheimer’s drug.

That glimpse, revealing a combination of declining sales, growing competition and failed medicines, underscores the stakes of the big biotech’s Aduhelm efforts, as execs punch back at the criticism they’ve engendered in the political and medical world and vigorously pushes its sales staff to roll out the drug as fast as possible.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

July 21, 2021 09:51 AM EDTUpdated July 23, 01:52 PM

R&D

Novartis discards one of its ‘wild card’ drugs after it flops in key study. But it takes one more for the hand

John Carroll

Editor & Founder

Always remember just how risky it is to gamble big on small studies.

A little more than 4 years ago, Novartis reportedly put up a package worth up to $1 billion for the dry eye drug ECF843 after a small biotech called Lubris put it through its paces in a tiny study of 40 moderate to severe patients, tracking some statistically significant markers of efficacy.

By last fall, the program had risen up to become one of CEO Vas Narasimhan’s top “wild card” programs in line for a potential breakthrough year in 2021. These drugs were all considered high-risk, high-reward efforts. And in this case, risk won.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

ENDPOINTS CAREERS

Director, High-Throughput Screening (HTS) Drug Discovery Group

Pliant Therapeutics

South San Francisco, CA, USA

view job offer post your job now

July 23, 2021 07:37 AM EDT

Pharma

Novartis to pay nearly $178M in lawsuit over BRAF drug — and will be on the hook for royalty

Josh Sullivan

Associate Editor

After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million.

Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful.

Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)

July 22, 2021 09:47 AM EDTUpdated 10:10 AM

Pharma

Biogen defends slow rollout of new Alzheimer's drug, criticizes negative media attention

Zachary Brennan

Senior Editor

As Biogen execs bemoaned the negative media coverage around Aduhelm’s approval a month ago, the biotech isn’t gaining much traction yet in using its new drug, largely due to a lack of insurance coverage, according to an earnings call Thursday.

Management indicated that of the nearly 900 sites that were prepped and ready following Aduhelm’s approval, 325 of those, or about 35%, have completed a positive pharmacy and therapeutics (P&T) review or won’t require one. The review is a step some hospitals or health systems take prior to using a new drug. Some major sites, however, have said they won’t participate.